Literature DB >> 29367998

Identification of a rhodium(iii) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells.

Guan-Jun Yang1, Hai-Jing Zhong, Chung-Nga Ko, Suk-Yu Wong, Kasipandi Vellaisamy, Min Ye, Dik-Lung Ma, Chung-Hang Leung.   

Abstract

The rhodium(iii) complex 1 was identified as a potent Wee1 inhibitor in vitro and in cellulo. It decreased Wee1 activity and unscheduled mitotic entry, and induced cell damage and death in TP53-mutated triple-negative breast cancer cells. 1 represents a promising scaffold for further development of more potent metal-based Wee1 antagonists.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29367998     DOI： 10.1039/c7cc09384e

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  9 in total

Review 1.  Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Rita Santamaria; Carlo Irace
Journal:  Pharmaceutics       Date:  2022-04-28       Impact factor: 6.525

Review 2.  Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

Authors:  Nazia Nayeem; Maria Contel
Journal:  Chemistry       Date:  2021-05-05       Impact factor: 5.020

3.  MIIP is downregulated in gastric cancer and its forced expression inhibits proliferation and invasion of gastric cancer cells in vitro and in vivo.

Authors:  Dan Sun; Yiwei Wang; Shanshan Jiang; Gang Wang; Yan Xin
Journal:  Onco Targets Ther       Date:  2018-12-11       Impact factor: 4.147

4.  Expression and biological function of rhotekin in gastric cancer through regulating p53 pathway.

Authors:  Meng-Yao Sun; Hong Zhang; Jie Tao; Zhen-Hua Ni; Qiu-Xue Wu; Qing-Feng Tang
Journal:  Cancer Manag Res       Date:  2019-01-25       Impact factor: 3.989

Review 5.  Pharmacological Inhibition of LSD1 for Cancer Treatment.

Authors:  Guan-Jun Yang; Pui-Man Lei; Suk-Yu Wong; Dik-Lung Ma; Chung-Hang Leung
Journal:  Molecules       Date:  2018-12-04       Impact factor: 4.411

6.  Inhibition of the CDK9-cyclin T1 protein-protein interaction as a new approach against triple-negative breast cancer.

Authors:  Sha-Sha Cheng; Yuan-Qing Qu; Jia Wu; Guan-Jun Yang; Hao Liu; Wanhe Wang; Qi Huang; Feng Chen; Guodong Li; Chun-Yuen Wong; Vincent Kam Wai Wong; Dik-Lung Ma; Chung-Hang Leung
Journal:  Acta Pharm Sin B       Date:  2021-10-30       Impact factor: 14.903

7.  Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein-protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells.

Authors:  Shasha Cheng; Guan-Jun Yang; Wanhe Wang; Dik-Lung Ma; Chung-Hang Leung
Journal:  Genes Dis       Date:  2021-07-10

Review 8.  Berberine as a potential agent for breast cancer therapy.

Authors:  Xiao-Dan Zhong; Li-Juan Chen; Xin-Yang Xu; Yan-Jun Liu; Fan Tao; Ming-Hui Zhu; Chang-Yun Li; Dan Zhao; Guan-Jun Yang; Jiong Chen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

Review 9.  A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance.

Authors:  Guan-Jun Yang; Yan-Jun Liu; Li-Jian Ding; Fan Tao; Ming-Hui Zhu; Zhen-Yuan Shi; Juan-Ming Wen; Meng-Yao Niu; Xiang Li; Zhan-Song Xu; Wan-Jia Qin; Chen-Jie Fei; Jiong Chen
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.